IDA blend vs Senegal: Access to anti-retroviral drugs, female
IDA blend
88.4%
in 2024
Senegal
98.0%
in 2024
IDA blend rank
3rd
Senegal rank
1st
Access to anti-retroviral drugs, female over time
- IDA blend
- Senegal
How they compare
Senegal currently reports 98.0% against 88.4% in IDA blend, a difference of 9.6%.
That makes Senegal's figure about 1.1 times IDA blend's.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Senegal ahead.
IDA blend ranks 3rd and Senegal ranks 1st of 19 groups.
Senegal has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | IDA blend | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.2% | 10.6% | 5.4% | Senegal |
| 2010s | 51.6% | 62.8% | 11.2% | Senegal |
| 2020s | 83.0% | 95.0% | 12.0% | Senegal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, IDA blend or Senegal?
- Senegal, at 98.0% against 88.4% in IDA blend as of 2024.
- What is the difference in access to anti-retroviral drugs, female between IDA blend and Senegal?
- 9.6%, with Senegal ahead.
- How many years of comparable data are there for IDA blend and Senegal?
- 25 years are reported by both, from 2000 to 2024.
- How do IDA blend and Senegal rank globally for access to anti-retroviral drugs, female?
- IDA blend ranks 3rd and Senegal ranks 1st of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.